• NovaBridge Biosciences Chief Medical Officer Dennis Phillip Andrew reported an RSU settlement into 23,695 ordinary shares on Sep. 17.
• He sold 8,209 ordinary shares on Sep. 18 at USD 0.71 per share.
• Directly owned ordinary shares ended at 173,427 following the transactions.
• Directly held restricted share units stood at 72,120 after the Sep. 17 vesting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002089237-26-000008), on September 21, 2026, and is solely responsible for the information contained therein.